Opinion statement
Clinically recognized disorders of glucose metabolism include impaired fasting glucose, impaired glucose tolerance (both termed prediabetes), and diabetes mellitus. Type 2 diabetes mellitus affects 6% to 13% of adults in the United States. Among patients with recent stroke, 70% will have known diabetes, occult diabetes (detectable on an oral glucose tolerance test), or prediabetes. Type 2 diabetes mellitus is associated with a two- to six-fold increased risk for first or recurrent ischemic stroke. The mechanisms for the association are myriad and include the effects of hyperglycemia on vascular tissues and coagulation, and aberrations in blood pressure regulation, lipid metabolism, endothelial function, vascular inflammation, lipid metabolism, smooth muscle cell proliferation, and fibrinolysis. The most effective strategies to prevent stroke among people with diabetes include blood pressure control, antiplatelet therapy, and statin therapy. Tight glycemic control is recommended to prevent microvascular disease, but the effect on macrovascular disease, including stroke, has not been proven. Target blood pressure should be less than 130/80. Antiplatelet therapy may be accomplished with 81 to 325 mg of aspirin daily or 75 mg of clopidogrel daily. Statins should be given in dosages effective to reduce lowdensity lipoprotein cholesterol to less than 100 mg/dL. For glycemic control, first line therapy for most patients is metformin, starting at 500 mg daily. With time, most patients will need two or three oral medications from different classes and many eventually will require insulin therapy. Prevention of diabetes may be best accomplished by identifying those at risk and modifying diet, weight, and exercise habits. Screening for prediabetes and diabetes is appropriate for men and women older than 45 years and all individuals with vascular disease. Insulin resistance and impaired insulin secretion is the major underlying defect in type 2 diabetes mellitus. It also affects 50% of nondiabetic subjects with a recent ischemic stroke. Emerging evidence has linked insulin resistance to the pathophysiologic derangements in type 2 diabetes mellitus that accelerate atherosclerosis. Treatment of insulin resistance with weight loss, exercise, or medication can correct these derangements, and represents a promising approach to stroke prevention.
Similar content being viewed by others
References and Recommended Reading
American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2004, 27(suppl 1):S15-S35. Each year in January, as a supplement to Diabetes Care, the ADA publishes updated versions of this influential article.
Narayan KMV, Boyle JP, Thompson TJ, et al.: Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290:1884–1890.
Goldstein LB, Adams R, Becker K, et al.: Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001, 32:280–299.
Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.
Kernan WN, Viscoli CM, Brass LM, et al.: The stroke prognosis instrument II (SPI-II): A clinical prediction instrument for patients with transient ischemic and nondisabling ischemic stroke. Stroke 2000, 31:456–462.
Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis. JAMA 2002, 287:2570–2581. This comprehensive review provides a contemporary understanding of the mechanisms that explain the association between diabetes and increased risk for vascular disease.
Kernan WN, Inzucchi SE, Viscoli CM, et al.: Insulin resistance and risk for stroke. Neurology 2002, 59:809–815.
Lindahl B, Dinesen B, Eliasson M, et al.: High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke 2000, 31:2936–2941.
Folsom AR, Rasmussen ML, Chambless LE, et al.: Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care 1999, 22:1077–1083.
Despres J-P, LaMarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952–957. This study, because of its superior research methods, provided important support for the hypothesis that insulin resistance is associated with increased risk for vascular disease.
Kernan WN, Viscoli CM, Inzucchi SE, et al.: Insulin resistance among patients with ischemic stroke and TIA. Stroke 2002, 33:389.
American Diabetes Association: Nutrition principles and recommendations in diabetes. Diabetes Care 2004, 27(suppl 1):S36-S46.
Wee CC: Physical activity counseling in primary care. The challenge of effecting behavioral change. JAMA 2001, 286:717–719.
Loreto CD, Fanelli C, Lucidi P, et al.: Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjects. Diabetes Care 2003, 26:404–408.
Expert Panel on the Identification Evaluation, and Treatment of Overweight and Obesity in Adults: Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998, 158:1855–1867.
The Heart Protection Study Collaboration Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003, 361:2005–2006.
UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854–865.
Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002, 287:360–372.
American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases: Prevention or delay of type 2 diabetes. Diabetes Care 2004, 27(suppl):S47-S54.
Buchanan TA, Xiang AH, Peters RK, et al.: Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone. Diabetes 2002, A81.
Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adult: Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.
Centers for Disease Control and Prevention. Prevalence of sedentary lifestyle — behavioral risk factor surveillance system, Unites States, 1991. MMWR Morb Mortal Wkly Rep 1993, 42:576–579.
Capes SE, Hunt D, Malmberg K, et al.: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients. A systematic overview. Stroke 2001, 32:2426–2432.
Bruno A, Levine SR, Frankel MR, et al.: Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002, 59:669–674.
Weir CJ, Murray GD, Dyker AG, Lees KR: Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ 1997, 314:1303–1306.
Baird TA, Parsons MW, Phanh T, et al.: Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 2003, 34:2208–2214.
Van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345:1359–1367.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kernan, W.N., Inzucchi, S.E. Type 2 diabetes mellitus and insulin resistance: Stroke prevention and management. Curr Treat Options Neurol 6, 443–450 (2004). https://doi.org/10.1007/s11940-004-0002-y
Issue Date:
DOI: https://doi.org/10.1007/s11940-004-0002-y